Purdue Pharma L.p.

Purdue Pharmaceuticals L.p.

The P.f. Laboratories, Inc.

Supernus Pharmaceuticals, Inc.

Euro-celtique S.a.

Christopher D Breder

Benjamin Oshlack

Curtis Wright

Robert D Colucci

Stephen A Howard

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.

Method of treatment of CNS disorders

The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.

Method of treatment of aggression

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Growing community of inventors

Bethesda, MD, United States of America

Christopher D Breder